- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02915029
Home-base Kidney Care in Zuni Indians (HBKC)
Reducing Health Disparity in Chronic Kidney Disease in Zuni Indians
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypothesis: (1) The Zuni Health Initiative (ZHI) can integrate an innovative approach to Home based kidney care (HBKC) utilizing tribal Community Health Representatives (CHRs), Point of Care (POC) technology, telemedicine and motivational messaging in conjunction with patient preferences and Patient Activation Measures (PAM) into the chronic care model to improve the detection and treatment of Chronic Kidney Disease (CKD) and related risk factors; (2) This model is generalizable to other high-risk communities e.g., Hispanic and American Indians in Guadalupe, AZ being studied by NIDDK, NIH-Phoenix.
Specific Aim 1: Re-phenotype prior participants, to identify incident cases of CKD, estimate progression rates, and identify participants for the proposed study of HBKC;
Specific Aim 2: Conduct a pilot study of HBKC in 120 people. Randomize households in a 1:1 allocation to usual care versus HBKC. Compare the changes in Patient Activation measure (PAM), Adherence, BP, weight, HbA1c, UACR, eGFR and lipid profiles between the two groups over the 1-year intervention period;
Specific Aim 3: Inform the design of the full-scale study by estimating anticipated recruitment, adherence and dropout rates, sample size and reassessing the approach;
Specific Aim 4: Assess the exportability of the HBKC model to Hispanics and American Indians in Guadalupe, AZ.
Study Outcomes: (1) The PAM and adherence; (2) Changes in clinical phenotypes including Cr, UACR, A1c, body weight, BMI, fasting glucose, blood pressure (BP), plasma lipids, and inflammatory markers; (3) Changes in the quantitative traits such as diet and scores from a battery of mental-health, self-efficacy, and quality of life instruments.
Health Impact: The active participation of the Zuni tribal leadership and IHS in this protocol, and the general affordability of Zuni native CHR personnel, render the outcomes that will be demonstrated by this proposal easily sustainable over the long term. If successful, this program has the potential to change best-practices for CKD progression and to reduce health disparities in a cost-effective and sustainable manner.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of diabetes
- Clinical diagnosis of microalbuminuria
- Must be living in a household with more than 1 living participant
- Age 21 to 80 years
- Must have negative pregnancy test in women of child-bearing potential
Exclusion Criteria:
- Life expectancy < 1 year
- On dialysis
- With renal transplant
- Pregnancy or absence of reliable birth control in women of child-bearing potential
- Malignancy except non-melanoma skin cancer
- Blind
- Unwilling or unable to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Education and Lifestyle Coaching
Education and life style coaching includes: education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence |
Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters. Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month. |
No Intervention: Usual care (UC) control arm
once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care.
The group gets labs and other survey done at 6 and 12 months of the intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Activation Measure (PAM) -13 Item Questionnaire
Time Frame: 12 months follow-up minus baseline values
|
Patient Activation Measure (PAM) questionnaire gives total score of activation as well as levels (stages) of patient activation. PAM total score can range form 0-100 with higher score reflecting higher level of activation in Patient health care. PAM levels (Stages) 1 through 4 with 1 being the lowest activation and 4 being the highest activation level. We collected data about Changes in PAM score as well as levels (stages) from baseline to 12 months of intervention and compare it to Usual care group. |
12 months follow-up minus baseline values
|
Patient Activation Measure (PAM) Level Greater Than 2
Time Frame: 12 months follow-up
|
Participants in an "Activated" category. Patient Activation Measure (PAM) questionnaire gives total score of activation as well as levels (stages) of patient activation. PAM total score can range form 0-100 with higher score reflecting higher level of activation in Patient health care. PAM levels (Stages) 1 through 4 with 1 being the lowest activation and 4 being the highest activation level. Level 1 labeled as patient being dis-engaged, Level 2 labeled as patient becoming aware of health condition but still struggling, level 3 labeled as patient is taking action and gaining control of their health care and level 4 labeled as maintaining behaviors and pushing forward - for our analysis purposes we classified participants into levels 3 and 4 (activated) and level 1 and 2 as not activated. We collected data about Changes in PAM score as well as levels (stages) from baseline to 12 months of intervention and compare it to Usual care group. |
12 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A1c
Time Frame: 12 months minus baseline values
|
Changes in clinical values
|
12 months minus baseline values
|
Diastolic Blood Pressure
Time Frame: 12 months minus baseline values
|
Changes in diastolic blood pressure on study.
|
12 months minus baseline values
|
Systolic Blood Pressure
Time Frame: 12 months minus baseline values
|
Changes in Systolic blood pressure over study.
|
12 months minus baseline values
|
Body Mass Index
Time Frame: 12 months minus baseline values
|
Changes in the value of body mass index (BMI)
|
12 months minus baseline values
|
Low-density Lipoprotein LDL Cholesterol
Time Frame: 12 months minus baseline values
|
Changes in serum LDL cholesterol on study
|
12 months minus baseline values
|
High-density Lipoprotein HDL Cholesterol
Time Frame: 12 months minus baseline values
|
Change in serum HDL cholesterol on study
|
12 months minus baseline values
|
Triglycerides
Time Frame: 12 months minus baseline values
|
Change in serum triglycerides on study
|
12 months minus baseline values
|
Serum Total Cholesterol
Time Frame: 12 months minus baseline values
|
Change in total cholesterol on study
|
12 months minus baseline values
|
High Sensitive C-reactive Protein-hsCRP
Time Frame: 12 months minus baseline values
|
Changes in the serum c-reactive protein on study
|
12 months minus baseline values
|
Serum Total Protein
Time Frame: 12 months minus baseline values
|
Change in total protein on study
|
12 months minus baseline values
|
eGFR
Time Frame: 12 months minus baseline values
|
Changes in estimated (via CKD-EPI) Glomerular Filtration Rate.
|
12 months minus baseline values
|
UACR
Time Frame: 12 months minus baseline values
|
change in urinary albumin to creatinine ratio on study.
|
12 months minus baseline values
|
KDQOL-Symptom/Problem
Time Frame: 12 months minus baseline values
|
Changes on study of symptom/problem list from quality of life (KDQOL-36).
Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD).
For all KDQOL scales, a higher score indicates better quality of life.
All domain scales can range from 0-100.
|
12 months minus baseline values
|
KDQOL-EKD
Time Frame: 12 months minus baseline values
|
Changes in effects of kidney disease score from quality of life (KDQOL).
Changes on study of effect of kidney disease from quality of life (KDQOL-36).
Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD).
For all KDQOL scales, a higher score indicates better quality of life.
All domain scales can range from 0-100.
|
12 months minus baseline values
|
KDQOL-BKD
Time Frame: 12 months minus baseline values
|
Change on study of burden of kidney disease score from KDQOL-36.
Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD).
For all KDQOL scales, a higher score indicates better quality of life.
All domain scales can range from 0-100.
|
12 months minus baseline values
|
KDQOL-SF12 Physical Score
Time Frame: 12 months minus baseline values
|
Changes on study of SF12 physical quality of life scale from the KDQOL-36.
Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD).
For all KDQOL scales, a higher score indicates better quality of life.
All domain scales can range from 0-100.
|
12 months minus baseline values
|
KDQOL-SF12 Mental Score
Time Frame: 12 months minus baseline values
|
Change on study of SF12 mental quality of life scale from the KDQOL-36 Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD).
For all KDQOL scales, a higher score indicates better quality of life.
All domain scales can range from 0-100.
|
12 months minus baseline values
|
8-Item Morisky Score
Time Frame: 12 months minus baseline values
|
Change in Morisky total score on study.The 8-item Morisky scale is a validated scale designed to estimate the risk of medication non-adherence. The Scale of the total score ranges from 0 to 8. We only report a total score. For a reported scale,
|
12 months minus baseline values
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Shah VO, Carroll C, Mals R, Ghahate D, Bobelu J, Sandy P, Colleran K, Schrader R, Faber T, Burge MR. A Home-Based Educational Intervention Improves Patient Activation Measures and Diabetes Health Indicators among Zuni Indians. PLoS One. 2015 May 8;10(5):e0125820. doi: 10.1371/journal.pone.0125820. eCollection 2015.
- Newman S, Cheng T, Ghahate DM, Bobelu J, Sandy P, Faber T, Shah VO. Assessing knowledge and attitudes of diabetes in Zuni Indians using a culture-centered approach. PLoS One. 2014 Jun 11;9(6):e99614. doi: 10.1371/journal.pone.0099614. eCollection 2014.
- Shah VO, Ghahate DM, Bobelu J, Sandy P, Newman S, Helitzer DL, Faber T, Zager P. Identifying barriers to healthcare to reduce health disparity in Zuni Indians using focus group conducted by community health workers. Clin Transl Sci. 2014 Feb;7(1):6-11. doi: 10.1111/cts.12127. Epub 2013 Nov 8.
- MacCluer JW, Scavini M, Shah VO, Cole SA, Laston SL, Voruganti VS, Paine SS, Eaton AJ, Comuzzie AG, Tentori F, Pathak DR, Bobelu A, Bobelu J, Ghahate D, Waikaniwa M, Zager PG. Heritability of measures of kidney disease among Zuni Indians: the Zuni Kidney Project. Am J Kidney Dis. 2010 Aug;56(2):289-302. doi: 10.1053/j.ajkd.2010.03.012. Epub 2010 Jun 19.
- Nelson RG, Pankratz VS, Ghahate DM, Bobelu J, Faber T, Shah VO. Home-Based Kidney Care, Patient Activation, and Risk Factors for CKD Progression in Zuni Indians: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1801-1809. doi: 10.2215/CJN.06910618. Epub 2018 Nov 15.
- Cukor D, Cohen LM, Cope EL, Ghahramani N, Hedayati SS, Hynes DM, Shah VO, Tentori F, Unruh M, Bobelu J, Cohen S, Dember LM, Faber T, Fischer MJ, Gallardo R, Germain MJ, Ghahate D, Grote N, Hartwell L, Heagerty P, Kimmel PL, Kutner N, Lawson S, Marr L, Nelson RG, Porter AC, Sandy P, Struminger BB, Subramanian L, Weisbord S, Young B, Mehrotra R. Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney Diseases. Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1703-12. doi: 10.2215/CJN.09780915. Epub 2016 May 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-249 -sub study HBKC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Educational and lifestyle coaching
-
Stanford UniversityRecruitingSelf Efficacy | Sleepiness | Lifestyle, Healthy | Work Related Stress | Alertness | Self-Compassion | Shift-Work Related Sleep DisturbanceUnited States
-
Radboud University Medical CenterActive, not recruiting
-
West Virginia School of Osteopathic MedicineNot yet recruitingHeart Failure | Hypertension | Obesity | Polycystic Ovary Syndrome | Metabolic Syndrome | Hyperlipidemias | Coronary Heart Disease | Depression, Anxiety | Type II DiabetesUnited States
-
University of the Basque Country (UPV/EHU)Universidad Pública de Navarra; Ministerio de Economía y Competitividad, SpainCompletedOverweight Children With Type 2 Diabetes RiskSpain
-
Massachusetts General HospitalCompletedObesity | Weight Loss | Telemedicine
-
The University of Texas Health Science Center,...National Cancer Institute (NCI); Washington University School of Medicine; Emory... and other collaboratorsCompletedChronic DiseaseUnited States
-
University of North Carolina, Chapel HillNational Cancer Institute (NCI); The University of Texas Health Science Center... and other collaboratorsCompletedChronic DiseaseUnited States
-
La Trobe UniversityRecruitingAnterior Cruciate Ligament Injuries | Concussion, Brain | Musculoskeletal InjuryAustralia
-
University of California, San DiegoCompletedHypertensionUnited States
-
Kaiser PermanenteCompletedHypertensionUnited States